Real‐World Disparities in Remote Follow‐Up of Cardiac Implantable Electronic Devices and Impact of the COVID‐19 Pandemic: A Single‐Center Experience
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.122.027500 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von H Immo Lehmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Massachusetts General Hospital Boston MA. Hauptthemen laut MEDLINE: Pacemaker, Artificial, COVID-19, Defibrillators, Implantable, Cardiac Resynchronization Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background Remote monitoring (RM) of cardiac implantable electronic devices has been shown to improve cardiovascular morbidity and mortality. To date, no studies have investigated disparities in use and delivery of RM. This study was performed to investigate if racial and socioeconomic disparities are present in cardiac implantable electronic device RM. Methods and Results This was a retrospective observational cohort study at a single tertiary care center in the United States. Patients who received a newly implanted cardiac implantable electronic device or device upgrade between January 2017 and December 2020 were included. Patients were classified as RM positive (RM+) when they underwent at least ≥2 remote interrogations per year during follow‐up. Of all eligible patients, 2520 patients were included, and 34% were women. The mean follow‐up was 25 months. Mean age was 71±14 years. Pacemakers constituted 66% of implanted devices, whereas 26% were implantable cardioverter‐defibrillators, and 8% were cardiac resynchronization therapy with implantable cardioverter‐defibrillators. Most patients (83%) were of European American ancestry. During follow‐up, 66% of patients were classified as RM+. Patients who were younger, European American, college‐educated, lived in a county with higher median household income, and were active on the hospital's patient portals were more frequently RM+. In an adjusted regression model, RM+ remained associated with the use of the online patient portal (odds ratio [OR], 2.889 [95% CI, 2.387–3.497]), presence of an implantable cardioverter‐defibrillator (OR, 1.489 [95% CI, 1.207–1.835]), advanced college degree (OR, 1.244 [95% CI, 1.014–1.527]), and lastly with European American ancestry ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology Massachusetts General Hospital Boston MA.
- Harvard Medical School Cambridge MA.
- Department of Medicine Massachusetts General Hospital Boston MA.
- Brigham and Women's Hospital Boston MA.
ORCID-Profile: H Immo Lehmann, Guoping Li, Jagmeet Singh, Theofanie Mela
Förderung
- NCATS NIH HHS
Zitieren
APA
Lehmann, H. I., Sharma, K., Bhatia, R., Mills, T., Lang, J., Li, G., Andrews, C., Cullivan, J., Singh, J., & Mela, T. (2023). Real‐World Disparities in Remote Follow‐Up of Cardiac Implantable Electronic Devices and Impact of the COVID‐19 Pandemic: A Single‐Center Experience. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.027500
Vancouver
Lehmann HI, Sharma K, Bhatia R, Mills T, Lang J, Li G, et al. Real‐World Disparities in Remote Follow‐Up of Cardiac Implantable Electronic Devices and Impact of the COVID‐19 Pandemic: A Single‐Center Experience. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.027500
BibTeX
@article{Lehmann2023,
author = {Lehmann, H Immo and Sharma, Krishan and Bhatia, Roma and Mills, Theresa and Lang, Joshua and Li, Guoping and Andrews, Carl and Cullivan, Jay and Singh, Jagmeet and Mela, Theofanie},
title = {Real‐World Disparities in Remote Follow‐Up of Cardiac Implantable Electronic Devices and Impact of the COVID‐19 Pandemic: A Single‐Center Experience},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.122.027500}
}
EUVIMED